Welcome to our dedicated page for Aclaris Therapeutics news (Ticker: ACRS), a resource for investors and traders seeking the latest updates and insights on Aclaris Therapeutics stock.
Aclaris Therapeutics Inc (NASDAQ: ACRS) generates news flow typical of clinical-stage biotechnology companies pursuing FDA approval for novel treatments. As a dermatology and immunology-focused biotech, news coverage centers on clinical trial milestones, regulatory interactions, and pipeline advancement.
Clinical trial updates represent the most significant news events for Aclaris. Phase 1, Phase 2, and Phase 3 trial initiations signal pipeline progression, while data readouts from completed studies often drive substantial investor interest. Positive efficacy results can validate the company's therapeutic approach, while safety data informs the risk-benefit profile of drug candidates.
Regulatory news includes FDA designation announcements, meeting outcomes, and submission updates. Fast Track or Breakthrough Therapy designations indicate FDA recognition of a drug's potential to address unmet medical needs. These designations can accelerate development timelines and generate investor attention.
Conference presentations at medical and investor conferences provide visibility into Aclaris's scientific progress. Late-breaking abstracts accepted at dermatology or immunology conferences signal noteworthy research findings. Investor conference participation offers management perspectives on corporate strategy and pipeline priorities.
Corporate developments include leadership appointments, financing transactions, and partnership announcements. For clinical-stage companies, cash position updates and equity offerings inform operational runway estimates. Strategic partnerships or licensing deals can validate pipeline assets and provide non-dilutive funding.
Quarterly earnings reports summarize financial position, R&D spending, and clinical progress. These reports contextualize cash burn rates against development timelines and upcoming catalysts.
Bookmark this page to follow Aclaris Therapeutics news as the company advances its dermatology and immunology pipeline through clinical development.
Aclaris Therapeutics has announced significant leadership changes effective January 1, 2023. Dr. Neal Walker will transition to Chair of the Board, while Dr. Douglas Manion is appointed CEO, succeeding Walker. Kevin Balthaser takes over as CFO following Frank Ruffo's retirement, and Matthew Rothman is appointed General Counsel. These transitions reflect Aclaris' strategic evolution in developing novel drug candidates for immuno-inflammatory diseases, emphasizing a leadership team with substantial pharmaceutical experience.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced participation in two healthcare investor conferences in November 2022. On November 16, at 5:00 PM GMT/12:00 PM EST, Dr. Neal Walker, CEO, will engage in a fireside chat at the Jefferies London Healthcare Conference.
Additionally, on November 29 at 9:30 AM EST, he will participate in another fireside chat at the 34th Annual Piper Sandler Healthcare Conference in New York. Webcasts for both events will be available on Aclaris' website and archived for 30 days.
Aclaris Therapeutics (NASDAQ: ACRS) announced significant developments in its drug pipeline, completing enrollment in the Phase 2a trial of zunsemetinib for hidradenitis suppurativa, with topline data expected in mid-2023. Additionally, the company reported a patent license agreement with Lilly, generating $17.6 million in revenue. Financially, Aclaris reported a net loss of $20.0 million for Q3 2022, an improvement from $21.1 million in Q3 2021, yet R&D expenses rose to $23.7 million due to ongoing clinical trials. The company’s cash reserves stand at $248.1 million, projected to fund operations through 2025.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced the appointment of Robert A. Doody Jr. as Vice President of Investor Relations on September 27, 2022. CEO Neal Walker expressed enthusiasm about strengthening the team with experienced industry veterans. Doody brings nearly 20 years of experience in biotechnology and has previously held investor relations positions at Provention Bio, Idera Pharmaceuticals, and ViroPharma. His expertise is expected to enhance Aclaris' engagement with investors as the company develops novel drug candidates for immuno-inflammatory diseases.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced that Dr. Neal Walker, CEO, will present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference. The virtual presentation will be accessible on-demand starting September 12, 2022, at 7:00 a.m. ET. Management will be available for virtual 1x1 meetings throughout the day. A webcast of the presentation will be available on Aclaris' website for at least 30 days. Aclaris focuses on developing innovative drug candidates for patients with immuno-inflammatory diseases.
Aclaris Therapeutics (NASDAQ: ACRS) announced a non-exclusive patent license agreement with Eli Lilly for the use of baricitinib, a JAK inhibitor, to treat alopecia areata. The deal includes an upfront payment, regulatory and commercial milestones, and royalties. Jim Loerop, Chief Business Officer, emphasized the significance of the patent portfolio for commercialization, highlighting Aclaris' investment in its JAK inhibitor patents. Financial terms remain undisclosed, but the partnership positions Aclaris favorably within the competitive landscape of immuno-inflammatory disease treatments.
Aclaris Therapeutics (NASDAQ: ACRS) announced key updates on August 3, 2022, including the appointment of Douglas Manion, M.D., as President and COO. The company initiated Phase 2a study activities for Psoriatic Arthritis and reported a net loss of $20.5 million for Q2 2022, an increase from $18.2 million in Q2 2021. Total revenue for the quarter was $1.5 million, down from $1.8 million year-over-year. R&D expenses surged to $18.8 million, driven by advancements in clinical trials. Aclaris's cash position is robust, with $256 million available, ensuring operations through 2025.
Aclaris Therapeutics announces the appointment of Douglas Manion, M.D., as President and COO, effective August 1, 2022. Dr. Manion, who has over 25 years of experience in the pharmaceutical industry, will oversee day-to-day operations and help shape the company’s strategic direction alongside CEO Neal Walker. His previous roles include leadership positions at Arena Pharmaceuticals and Bristol-Myers Squibb. This leadership change aims to strengthen Aclaris' R&D capabilities and advance its pipeline of drug candidates for immuno-inflammatory diseases.
Aclaris Therapeutics, Inc. announces the appointment of Gail Cawkwell, MD, PhD, as its new Chief Medical Officer, effective June 27, 2022. Dr. Cawkwell brings over 20 years of experience in pharmaceutical development, most recently as Senior Vice President at Intercept Pharmaceuticals. Her expertise includes working in various disease areas and includes a strong clinical background. The company aims to leverage her leadership to advance its clinical pipeline, focusing on treatments for immuno-inflammatory diseases.
Aclaris Therapeutics, a clinical-stage biopharmaceutical firm focused on immuno-inflammatory diseases, announced that Dr. Neal Walker, President and CEO, will participate in a fireside chat at the Jefferies Healthcare Conference on June 8, 2022, at 11:30 a.m. ET in New York. The session will also allow for 1x1 meetings on the same day. A live webcast of the chat will be available on Aclaris’ website and archived for 30 days. The company is known for its innovative drug candidates aimed at addressing unmet patient needs in this therapeutic area.
FAQ
What is the current stock price of Aclaris Therapeutics (ACRS)?
What is the market cap of Aclaris Therapeutics (ACRS)?
